Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet Only preliminary foundational data below
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Seaport Therapeutics, Inc. (SPTX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Seaport Therapeutics, Inc.

SPTX NASDAQ
Healthcare · Biotechnology
Boston, MA 02210-2186, United States seaporttx.com Updated Aug 13, 2:51pm
Price
$23.68
Market Cap
$1.3B
Employees
58
Beta
—
Avg Volume
121,296
CEO
Ms. Daphne Zohar
GICS Category PDF

Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company employs its proprietary Glyph platform to address limitations of clinically validated mechanisms, such as high first-pass metabolism, low bioavailability, and side effects, enabling innovative therapies with established efficacy and safety profiles. Seaport Therapeutics targets the neuropsychiatry sector within pharmaceuticals and biotech, aiming to deliver leading treatment options that improve patient outcomes. Its pipeline advances antidepressants and anxiolytics derived from these optimized mechanisms. With a team experienced in neuropsychiatry drug discovery and development, Seaport Therapeutics operates at the intersection of cutting-edge platform technology and targeted therapeutic innovation. Founded in 2024 and headquartered in Boston, Massachusetts, the company plays a role in advancing accessible oral treatments for serious mental health conditions in the competitive biopharmaceutical market.

Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 13
No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Aug 3, 2026.
EPS surprise history — vs analyst consensus · 2 prints of vendor history
-166.5%
Jun '26
-169.7%
Aug '26
Print date EPS est. EPS actual Revenue est. Revenue actual
Aug 3, 2026 $-0.66 $-1.78 -169.7% — —
Jun 8, 2026 $-3.88 $-10.34 -166.5% — —

Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.

Recent SEC Filings
Filed Form Document
Aug 5, 2026 SCHEDULE 13G View
Aug 5, 2026 SCHEDULE 13G View
Aug 3, 2026 10-Q View
Aug 3, 2026 8-K View
Jun 24, 2026 4 View
Jun 8, 2026 10-Q View
Jun 8, 2026 8-K View
May 11, 2026 SCHEDULE 13D View
May 11, 2026 SCHEDULE 13G View
May 6, 2026 3 View
May 6, 2026 3 View
May 6, 2026 4 View

Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.

Price Overview
Last updated: Aug 13, 2026 2:51pm (just now)
Current data · timestamped when a report runs
$23.68
Change · Aug 13
-0.12 (-0.50%)
Day Range
$23.15 – $24.48
52-Week Range
$14.85 – $24.65
50-Day MA
$20.13
200-Day MA
—
Volume
3,102.00
Share Structure
Outstanding 53,027,817.00
Float 28,220,235.00
Free Float 53.2%
Normal free float — 53.2% of shares trade freely, ~46.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Last updated: Aug 13, 2026 2:51pm (just now)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 12, 2026 9:50am (1d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
-12.21
Stock Price: $23.68
EPS (Diluted): -1.94
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
—
Stock Price: $23.68
Total Equity: -$92.55M
Shares: 38,598,454
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
-9.24
Market Cap: $1.27B
Total Debt: $5.08M
Cash: $46.04M
EBITDA: -$85.89M
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$793.4M
Market Cap: $1.27B
Total Debt: $5.08M
Cash: $46.04M
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
—
Gross Profit: N/A
Revenue: $0.00
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
—
Operating Income: -$87.29M
Revenue: $0.00
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
—
Net Income: -$74.88M
Revenue: $0.00
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
—
Net Income: -$74.88M
Total Equity: -$92.55M
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
—
Operating Income: -$87.29M
Tax Rate: -1.0%
Equity: -$92.55M
Total Debt: $5.08M
Cash: $46.04M
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
17.46
Current Assets: $223.23M
Current Liabilities: $12.78M
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
—
Short-Term Debt: $1.64M
Long-Term Debt: $3.44M
Total Debt: $5.08M
Total Equity: -$92.55M
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 38,598,454
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
—
Total Equity: -$92.55M
Shares: 38,598,454
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$-2.02
Operating CF: -$77.94M
CapEx: $0.00
Shares: 38,598,454
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $23.68
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$74.88M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 12, 2026 9:50am (1d ago)
Metric 2024 2025
Revenue $0 $0
Cost of Revenue — —
Gross Profit — —
Operating Expenses $52.4M $87.3M
Operating Income -$52.4M -$87.3M
Net Income -$46.9M -$74.9M
EBITDA -$52.2M -$85.9M
EPS $-1.21 $-1.94
EPS (Diluted) $-1.21 $-1.94
Balance Sheet (Annual)
Last updated: Aug 12, 2026 9:50am (1d ago)
Metric 2024 2025
Cash & Equivalents $309.1M $46.0M
Total Current Assets $310.2M $223.2M
Total Assets $315.8M $249.0M
Current Liabilities $11.1M $12.8M
Long-Term Debt $4.1M $3.4M
Total Liabilities $340.6M $341.6M
Total Equity -$24.8M -$92.5M
Retained Earnings -$39.2M -$114.1M
Cash Flow (Annual)
Last updated: Aug 12, 2026 9:50am (1d ago)
Metric 2024 2025
Operating Cash Flow -$29.6M -$77.9M
Capital Expenditure — —
Free Cash Flow -$29.7M -$78.3M
Acquisitions (net) — —
Net Debt Issued / (Repaid) — —
Dividends Paid — —
Stock Buybacks — —
Net Change in Cash $309.7M -$263.1M
Growth Trends (YoY %)
Last updated: Aug 12, 2026 9:50am (1d ago)
Metric 2025
Revenue Growth —
Gross Profit Growth —
Operating Income Growth -66.5%
Net Income Growth -59.7%
EBITDA Growth -64.5%
Industry Benchmarks
Compares SPTX against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SPTX — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for SPTX — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for SPTX — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for SPTX — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for SPTX. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.530 · 761561a2 · 2026-08-12 19:06:35